Life sciences · Journal article
Journal of the American Chemical Society · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Tumor cells display a strong dependency on nutrients, yet nutrient-deprivation strategies often fail due to their metabolic plasticity and compensatory mechanisms, and can even promote invasion and metastasis. Here, we propose a metabolic therapeutic strategy that leverages rather than suppresses tumor nutrient addiction, termed “pseudo-overnutrition”. This approach induces tumor cells to continuously uptake nutrient analogs that cannot be effectively utilized, thereby decoupling nutrient input from nutrient utilization and triggering metabolic collapse. To validate this concept, we designed and assembled rare-earth–coordinated glutamine nanoparticles (RE-Gln). RE-Gln preferentially interacts with glutamine transporters on tumor-cell membranes, is subsequently internalized predominantly through macropinocytosis, and accumulates within lysosomes. The progressive accumulation of RE-Gln disrupts V-ATPase–dependent lysosomal nutrient sensing and blocks mTORC1 activation, rendering cells unable to effectively utilize nutrients despite continuous uptake. Importantly, the resulting dysfunction is confined primarily to lysosomes, while mitochondrial integrity remains preserved. This lysosome-centered impairment ultimately causes widespread disruption of glutamine and glucose metabolism. Moreover, the high-glutamine microenvironment induced by RE-Gln impairs lysosomal biogenesis and function in dendritic cells, enhancing antigen presentation and activating antitumor immunity. These findings establish “pseudo-overnutrition” as a previously unrecognized concept for metabolic intervention in cancer and provide a mechanistic framework for converting tumor nutrient dependency into a therapeutic vulnerability.